secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-10-13T12:36:31+00:00
Accession:  0001437749-26-032502
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CervoMed reports Phase 2a nfvPPA data: plasma NfL fell ~3.1 pg/mL over 12 weeks; 24-week data Nov 2026
--------------------------------------------------------------------------------

- Open-label Phase 2a in nfvPPA (NCT07033481): 25 participants; neflamapimod 40 mg TID (n=19) or 80 mg BID (n=6) for 24 weeks, then 12-week randomized withdrawal.
- Baseline: 18/25 (72%) had elevated NfL; mean NfL 45.7 pg/mL (SD 39.6); 4/25 (16%) elevated GFAP, mean 103.4 pg/mL (SD 43.2).
- Mean plasma NfL fell ~3.1 pg/mL over 12 weeks; in 13 participants with baseline NfL at/above median, mean reduction was ~5.7 pg/mL. GFAP stable.
- Neflamapimod generally well tolerated; one patient with elevated liver enzymes met discontinuation criteria, asymptomatic, resolved after stopping; no new safety signals.
- 24-week biomarker data to be presented at CTAD in November 2026; topline clinical data expected Q1 2027. nfvPPA has no approved US/EU treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/0001437749-26-032502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/crvo20261012_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer